More than 10 years after its discovery, a special type of stem cell is being put to the test.

In 2014 scientists in Japan launched the world’s first clinical trials using the cells, called induced pluripotent stem cells, and now scientists in the United States are in the run-up to this country’s first trial. iPS cells, as they are known, start as another type of cell — often blood or skin — before scientists coax them back into becoming stem cells. From there, researchers can then steer them to differentiate into another type of cell, building a vast wave of hope for the cells’ therapeutic potential.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy